

Table of Contents

ANALYSIS OF ICD-9 PROCEDURE DATA	6
METHODOLOGY	6
DATA SOURCE AND LIMITATIONS	7
INPATIENT INTERVENTIONAL MARKET BY TYPE OF PROCEDURE	7
2008 INPATIENT PROCEDURES	7
ENDOVASCULAR GAINS SHARE FROM SURGERY 1997-2008	9
PRIMARY AMPUTATION REMAINS A HIGH PERCENTAGE OF PROCEDURES	10
OVERVIEW OF 2008 INPATIENT INTERVENTIONAL MARKET BY VASCULAR TERRITORY	11
REVASCULARIZATION PROCEDURES SUITABLE FOR TREATMENT WITH ANGIOPLASTY OR ATHERECTOMY	12
AORTOILIAC OR PELVIC DISEASE	12
<i>Disease Characteristics</i>	12
<i>Procedures</i>	12
ABOVE KNEE—FEMOROPOPLITEAL DISEASE	14
<i>Disease Characteristics</i>	14
<i>Procedures</i>	15
BELOW KNEE—TIBIAL AND PERONEAL DISEASE	16
<i>Disease Characteristics</i>	16
<i>Procedures</i>	17
AMPUTATION.....	19
ANALYSIS OF STENTING IN THE LOWER LIMBS	19
ESTIMATED OUTPATIENT ENDOVASCULAR PROCEDURES 2008.....	20
METHOD AND ASSUMPTIONS	20
INPATIENT AND OUTPATIENT ENDOVASCULAR PROCEDURES BY VASCULAR TERRITORY	21
ENDOVASCULAR PROCEDURES BY DEVICE TYPE AND TERRITORY	22
SUMMARY OF INPATIENT AND OUTPATIENT REVASCULARIZATION MARKET.....	24
ENDOVASCULAR BY TYPE OF PROCEDURE	24
<i>Analysis of Angioplasty and Atherectomy Procedures 2003-2008</i>	25
ENDOVASCULAR AND SURGICAL MARKET BY TYPE OF PROCEDURE	25
U.S. PAD PROJECTIONS 2005-2020	26
MARKET POTENTIAL FOR REVASCULARIZATION PROCEDURES.....	27
ASSUMPTIONS EMPLOYED TO CALCULATE MARKET POTENTIAL.....	27
ENDOVASCULAR TO GAIN SHARE OF REVASCULARIZATION MARKET	28
POTENTIAL REVASCULARIZATION PROCEDURES 2005-2020	30
U.S. PAD MARKET POTENTIAL BY TYPE OF PROCEDURE.....	30

ENDOVASCULAR MARKET PROJECTIONS BY VASCULAR TERRITORY	31
ASSUMPTIONS	31
PERCENTAGE OF PATIENTS REVASCULARIZED REMAINS CONSTANT	31
PERCENTAGE OF PATIENTS DIAGNOSED AND TREATED PROJECTED TO INCREASE.....	32
<i>Reflects Technological Innovation and Growing Knowledge and Awareness of PAD</i>	<i>32</i>
BELOW KNEE ANGIOPLASTY/ATHERECTOMY PROCEDURES TO EXPAND FASTER THAN	
THOSE IN OTHER VASCULAR TERRITORIES.....	33
ENDOVASCULAR PATIENTS TREATED WITH ANGIOPLASTY/ATHERECTOMY OR PRIMARY	
STENTS	33
FUTURE ROLE OF PRIMARY STENTING	33
AORTOILIAC PRIMARY STENTING PROJECTED TO CONTINUE SHARE GAINS	33
INFRAINGUINAL PRIMARY STENTING: TWO ALTERNATIVE SCENARIOS	33
INFRAINGUINAL PRIMARY STENTING GAINS SHARE	34
INFRAINGUINAL PRIMARY STENTING DECLINES	34
AORTOILIAC ENDOVASCULAR PROCEDURES 2003-2020.....	36
PRIMARY STENTING GAINS SHARE RAPIDLY	36
PRIMARY STENTING GAINS SHARE MODERATELY.....	37
ABOVE KNEE ENDOVASCULAR PROCEDURES 2003-2020	39
PRIMARY STENTING GAINS SHARE	39
PRIMARY STENTING LOSES SHARE	40
BELOW KNEE ENDOVASCULAR PROCEDURES 2003-2020	42
PRIMARY STENTING GAINS SHARE	42
PRIMARY STENTING LOSES SHARE	43
DOLLAR VALUE OF THE PAD ENDOVASCULAR MARKET	45
APPENDIX A	47
HEALTHCARE COST AND UTILIZATION PROJECT.....	47
APPENDIX B	48
INPATIENT ENDOVASCULAR PROCEDURE ANALYSIS INCLUDING PROVISIONAL STENTS.....	48
APPENDIX C	51
MODIFICATIONS IN KEY ASSUMPTIONS	51
<i>Percentage of Ambulatory Endovascular Procedures.....</i>	<i>51</i>
<i>2009-2020 Projections.....</i>	<i>52</i>
REFERENCES.....	53
INDEX OF TABLES	57
INDEX OF FIGURES	59
DISCLOSURE STATEMENT	60

STOCK OWNERSHIP.....	60
CONTACT INFORMATION.....	61